CN107530445B - 用于蛋白质递送的隐形纳米胶囊 - Google Patents

用于蛋白质递送的隐形纳米胶囊 Download PDF

Info

Publication number
CN107530445B
CN107530445B CN201580074565.7A CN201580074565A CN107530445B CN 107530445 B CN107530445 B CN 107530445B CN 201580074565 A CN201580074565 A CN 201580074565A CN 107530445 B CN107530445 B CN 107530445B
Authority
CN
China
Prior art keywords
pmpc
protein
layer
encapsulated
native
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580074565.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN107530445A (zh
Inventor
Y.陆
Y.刘
J.温
G.刘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California, San Diego
Original Assignee
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, San Diego filed Critical University of California, San Diego
Publication of CN107530445A publication Critical patent/CN107530445A/zh
Application granted granted Critical
Publication of CN107530445B publication Critical patent/CN107530445B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F230/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and containing phosphorus, selenium, tellurium or a metal
    • C08F230/02—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and containing phosphorus, selenium, tellurium or a metal containing phosphorus
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L33/00—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
    • C08L33/04—Homopolymers or copolymers of esters
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D4/00—Coating compositions, e.g. paints, varnishes or lacquers, based on organic non-macromolecular compounds having at least one polymerisable carbon-to-carbon unsaturated bond ; Coating compositions, based on monomers of macromolecular compounds of groups C09D183/00 - C09D183/16
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Materials Engineering (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201580074565.7A 2014-11-26 2015-11-20 用于蛋白质递送的隐形纳米胶囊 Active CN107530445B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462084887P 2014-11-26 2014-11-26
US62/084,887 2014-11-26
PCT/US2015/061838 WO2016085808A1 (en) 2014-11-26 2015-11-20 Stealth nanocapsules for protein delivery

Publications (2)

Publication Number Publication Date
CN107530445A CN107530445A (zh) 2018-01-02
CN107530445B true CN107530445B (zh) 2021-01-05

Family

ID=56074921

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580074565.7A Active CN107530445B (zh) 2014-11-26 2015-11-20 用于蛋白质递送的隐形纳米胶囊

Country Status (5)

Country Link
US (1) US10722475B2 (cg-RX-API-DMAC10.html)
EP (1) EP3223802A4 (cg-RX-API-DMAC10.html)
JP (1) JP6802157B2 (cg-RX-API-DMAC10.html)
CN (1) CN107530445B (cg-RX-API-DMAC10.html)
WO (1) WO2016085808A1 (cg-RX-API-DMAC10.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017106380A1 (en) 2015-12-18 2017-06-22 The Regents Of The University Of California Protein nanocapsules with detachable zwitterionic coating for protein delivery
JP6784973B2 (ja) * 2017-03-30 2020-11-18 国立研究開発法人産業技術総合研究所 単層カーボンナノチューブ
CA3070242A1 (en) 2017-07-18 2019-01-24 Calimmune, Inc. Compositions and methods for treating beta-hemoglobinopathies
US20190351068A1 (en) * 2017-11-29 2019-11-21 Shen Pang Compositions and methods for drug delivery
EP3897831A1 (en) 2018-12-23 2021-10-27 CSL Behring LLC Donor t-cells with kill switch
CN109954128A (zh) * 2019-03-08 2019-07-02 南开大学 一种可干扰β-淀粉样蛋白聚集并协助清除的功能化纳米凝胶及制备方法
JP7226787B2 (ja) * 2019-04-26 2023-02-21 学校法人 関西大学 ハイドロゲルおよびその作製方法
WO2021263070A1 (en) 2020-06-26 2021-12-30 Csl Behring Llc Donor t-cells with kill switch
CN112516304B (zh) * 2020-12-29 2023-02-03 天津医科大学总医院 包裹静脉注射免疫球蛋白的纳米微囊和制备方法及其在制备治疗缺血性脑卒药物中的用途
JPWO2022255479A1 (cg-RX-API-DMAC10.html) * 2021-06-04 2022-12-08
CN116920117A (zh) * 2022-04-14 2023-10-24 上海巴久巴生物技术有限公司 一种与光动力染料结合的过氧化氢酶纳米胶囊，制备方法及应用
CN116549417A (zh) * 2022-09-07 2023-08-08 北京化工大学 一种靶向肿瘤微环境的v9302修饰的纳米胶囊、制备及应用
CN119770675A (zh) * 2023-10-06 2025-04-08 张铭 一种乳酸氧化酶纳米胶囊及其制备方法
CN119837820B (zh) * 2023-12-13 2025-10-10 上海交通大学 一种基于蛋白载体的活性成分透皮递送系统及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPH11322857A (ja) * 1998-05-08 1999-11-26 Nof Corp 静電結合型高分子複合体および製造方法
SI1988910T1 (en) 2006-02-28 2018-02-28 Kodiak Sciences Inc. Polymeric conjugates containing acryloyloxyethylphosphorylcholine and their preparations
EP2118150B1 (en) * 2007-02-14 2015-09-23 Biocompatibles UK Limited Derivatisation of biological molecules
CN101584860A (zh) * 2009-04-27 2009-11-25 西安杰诺瓦生物科技有限公司 重组人Claudin18.2肿瘤疫苗及其制备方法
EP2260873B1 (en) * 2009-06-08 2019-07-24 Biocompatibles UK Limited Pcylation of proteins
US9283194B2 (en) 2010-04-16 2016-03-15 The Regents Of The University Of California Methods for protease assisted protein delivery
JP2014522649A (ja) 2011-07-06 2014-09-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 多酵素ナノ複合体
WO2013022838A1 (en) 2011-08-05 2013-02-14 The Regents Of The University Of California Non-immunogenic positron emission tomography reporter gene systems
US9993440B2 (en) 2011-09-02 2018-06-12 The Regents Of The University Of California Enzyme responsive nanocapsules for protein delivery
AU2013358922B2 (en) 2012-12-14 2019-08-22 The Regents Of The University Of California Viral vector nanocapsule for targeting gene therapy and its preparation
CN103483480B (zh) * 2013-09-13 2015-09-02 苏州维泰生物技术有限公司 一种可应用于光诱导枝接的人造细胞膜材料及其合成方法

Also Published As

Publication number Publication date
CN107530445A (zh) 2018-01-02
JP2017535581A (ja) 2017-11-30
EP3223802A4 (en) 2018-07-04
WO2016085808A1 (en) 2016-06-02
US10722475B2 (en) 2020-07-28
EP3223802A1 (en) 2017-10-04
US20170354613A1 (en) 2017-12-14
JP6802157B2 (ja) 2020-12-16

Similar Documents

Publication Publication Date Title
US10722475B2 (en) Stealth nanocapsules for protein delivery
Jain et al. Comparison of avidin, neutravidin, and streptavidin as nanocarriers for efficient siRNA delivery
Joo et al. Porous silicon–graphene oxide core–shell nanoparticles for targeted delivery of siRNA to the injured brain
Quarta et al. Polymer coated inorganic nanoparticles: tailoring the nanocrystal surface for designing nanoprobes with biological implications
Zhang et al. Prolonging the plasma circulation of proteins by nano-encapsulation with phosphorylcholine-based polymer
Zhang et al. Polycation-functionalized nanoporous silicon particles for gene silencing on breast cancer cells
Leonard et al. Screening of budesonide nanoformulations for treatment of inflammatory bowel disease in an inflamed 3D cell-culture model
Li et al. Weaving enzymes with polymeric shells for biomedical applications
WO2015042204A1 (en) Enzyme-encapsulated nanoparticle platform
Nifontova et al. Structure–function relationships in polymeric multilayer capsules designed for cancer drug delivery
WO2023142357A1 (zh) 药物及siRNA共递送纳米复合物及其制备方法与应用
CN104725478B (zh) 多肽化合物、多肽化合物与siRNA的组装体及其应用
US10918718B2 (en) Sonosensitive therapeutic or diagnostic agent
Khemariya et al. New-fangled approach in the management of Alzheimer by formulation of polysorbate 80 coated chitosan nanoparticles of rivastigmine for brain delivery and their in vivo evaluation
Jain et al. Chitosan in the light of nanobiotechnology: a mini review
Steffè et al. Supramolecular dextran/polyamine phosphate nanocapsules with smart responsiveness for encapsulation of therapeutics
WO2018228464A1 (zh) 一种肿瘤靶向的纳米微囊及其制备方法和应用
Zhang et al. Enhanced anti-metastatic therapy with down-regulation of heparinase expression by ROS-responsive micellar nanoparticles
US20150110882A1 (en) Multifunctional metallic nanostructure and method for manufacturing the same
CN102264353A (zh) 炎症靶向颗粒
Zhao et al. Packaging cordycepin phycocyanin micelles for the inhibition of brain cancer
Nguyen et al. Harnessing the versatility of PLGA nanoparticles for targeted Cre-mediated recombination
CN116042707B (zh) 一种t细胞基因编辑的方法及应用
Angela et al. Nanodiamond‐Enabled Drug Delivery
Bolocan et al. In vitro and in vivo applications of 3D dendritic gold nanostructures

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant